BOLD Boundless Bio

Boundless Bio Reported Earnings

Tuesday, November 10, 2026 · 12:00 AM ET

Boundless Bio (BOLD) reported a loss of $0.23 per share on revenue of $0.00 million for the . .

Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients.

Earnings Whisper Grade

Power Rating

Reported Earnings

($0.23)

Earnings Whisper^®

—

Consensus Estimate

—

Earnings Surprise

Earnings Growth

Reported Revenue

—

Revenue Estimate

—

Revenue Surprise

Revenue Growth—

*Reported earnings and revenue figures shown above, and any guidance given, are preliminary and may be updated upon further review.*